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Abstract
Background: High risk type human papilloma viruses (HR-HPV) induce carcinomas of the uterine cervix by
expressing viral oncogenes E6 and E7. Oncogene E7 of HR-HPV disrupts the pRb/E2F interaction, which negatively
regulates the S phase entry. Expression of tumor suppressor p16ink4a drastically increases in majority of HR-HPV
associated carcinomas due to removal of pRb repression. The p16ink4a overexpression is an indicator of an
aberrant expression of viral oncogenes and may serve as a marker for early diagnostic of cervical cancer. On the
other hand, in 25–57% of cervical carcinomas hypermethylation of the p16 INK4a promoter has been
demonstrated using a methylation-specific PCR, MSP. To evaluate a potential usage of the p16 INK4a 5' CpG island
hypermethylation as an indicator of tumor cell along with p16ink4a overexpression, we analyzed the methylation
status of p16 INK4a in cervical carcinomas
Methods: Methylation status of p16 INK4a was analyzed by MSP and by bisulfite-modified DNA sequencing. The
expression of p16ink4a was analyzed by RT-PCR and by immunohistochemical technique.
Results: The extensive methylation within p16 INK4a 5' CpG island was not detected either in 13 primary
cervical carcinomas or in 5 cancer cell lines by bisulfite-modified DNA sequencing (including those that were
positive by MSP in our hands). The number and distribution of rare partially methylated CpG sites did not differ
considerably in tumors and adjacent normal tissues. The levels of the p16 INK4a mRNA were increased in
carcinomas compared to the normal tissues independently of the number of partially methylated CpGs within
5'CpG island. The transcriptional activation of p16 INK4a was accompanied by p16ink4a cytoplasmic
immunoreactivity in the majority of tumor cells and presence of a varied number of the p16 positive nuclei in
different tumors.
Conclusion: Hypermethylaion of the p16INK4a 5' CpG island is not a frequent event in HR-HPV-positive cervical
carcinomas and cannot be an effective marker of cancer cells with up-regulated expression of p16ink4a. Our data
confirm other previous studies claiming specific p16INK4a up-regulation in the majority of cervical carcinomas at
both the protein and mRNA levels. Cytoplasmic accumulation of p16ink4a is a feature of cervical carcinomas.
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The inhibitor of cyclin-dependent kinases p16ink4a is a
component of p16ink4a-Cdk4-6/cyclinD-pRb signaling
pathway, which is perturbed in many tumors. In normal
cells p16ink4a functions as a negative regulator of cell cycle
progression by controlling the activity of tumor suppres-
sor pRb. P16ink4a inhibits phosphorylation of pRb by
cyclinD-Cdk4/Cdk6 complexes. Hypophosphorylated
pRB binds to E2F transcription factors and inhibits them
in G0 and early G1 phases of cell cycle. In proliferating
cells phosphorylation of pRb releases E2F and induces
genes that mediate S phase entry. In tumor cells the pRB-
E2F interaction may be distured by different ways, includ-
ing mutations or inappropriate phosphorylation of pRb
due to Cdk4 orCdk6 kinases overexpression or loss of the
p16ink4a inhibitor [1]. The function of p16ink4a may be lost
due to the mutations or suppression of the transcription
by promoter methylation in different type of tumors [2-
4]. As a rule, simultaneous inactivation of both pRb and
p16ink4a does not occur in a single tumor [5,6]. A regula-
tory feedback exists in the pRb/p16 pathway: transcrip-
tion of p16 INK4a is repressed by p Rb. In tumor cells
lacking the pRb function the p16 INK4a transcription is
activated due to the removal of the pRb repression. [7,8].
The p16ink4a overexpression cannot inhibit cell cycle pro-
gression in these tumor cells in the absence of pRb.
Mechanism for inactivation of p16ink4a/pRb signaling
pathway in HR-HPV-positive cervical tumors differs from
that in virus-negative tumors. High risk type human pap-
illoma viruses induce carcinomas by expressing viral
oncogenes E6 and E7. Infections with HR-HPVs are
extremely widespread in the world but malignant trans-
formation is a rare consequence of infection and is associ-
ated with the aberrant expression of viral oncogenes in
basal and parabasal epithelial cells [9,10]. Continued E6/
E7 expression at a relatively high level is necessary for the
maintenance of the transformed phenotype of epithelial
cells [11,12]. Oncogene E7 of HR-HPV disrupts pRb/E2F
interaction, releases active E2F and induces the pRb degra-
dation through a proteasome-dependent mechanism
[13,14]. Thus, the level of pRb is decreased drastically and
the protein is not revealed by immunohistochemical tech-
nique in the majority of cancer cells in HR-HPV-positive
cervical tumors [6,15]. Due to the unified mode of inacti-
vation of the pRb/p16 pathway and existence of the regu-
latory feedback the vast majority of HR-HPV-positive
cervical tumors display strong a p16ink4a expression. The
p16ink4a overexpression is an indicator of aberrant expres-
sion of viral oncogenes and HPV-induced transformation
of epithelial cells [10]. Several research groups (including
us) have demonstrated by immunohistochemical tech-
nique a manifold increase of the p16ink4a expression in
cervical dysplasia and carcinomas in comparison with
that in normal epithelium [16-19] There is an abundant
evidence demonstrating that immunohisto-/cytochemical
detection of the protein p16ink4a is a promising test for
revealing the HPV-infected cells with malignant potential
[[10,20], for review see [21]]. Thus, the detection of the
protein p16ink4a overexpression is especially useful for
early diagnostics of HR-HPV-associated cervical cancer.
Along with the detection of p16ink4a expression in the
majority of the HR-HPV-positive cervical tumors, hyper-
methylation of p16 INK4a promoter has been demon-
strated in 25–57% of cervical carcinomas by methylation-
specific PCR, MSP [22-27]. Hypermathylation of p16
INK4a promoter is a well known mechanism of suppres-
sion of the gene transcription [4,5]. The co-existence of
both p16ink4a overexpression and hypermethylation of
gene promoter in a cervical cancer needs to be further
examined.
To evaluate potential of the p16 INK4a 5' CpG island
hypermethylation usage as an indicator of tumor cell
along with p16ink4aexpression, we analyzed the methyla-
tion status of the p16 INK4a promoter region by MSP and
bisulfite sequencing and expression by RT-PCR and
immunohistochemical technique in HR-HPV-positive
cervical tumors and cervical carcinoma cell lines.
Methods
Tissue specimens
Twenty six squamous cell carcinomas (SCC) of uterine
cervix and 14 specimens of adjacent normal tissues from
patients with I, II and III FIGO stages of disease were col-
lected under the approval of the Institutional Review
Board of the Blochin Cancer Research Center. Informed
consent was obtained from the patients prior to surgery.
All tumors were HPV16/18-positive and E7 viral genes
were expressed in all of them according to PCR analysis.
Cell lines
The human cervical carcinoma cells HeLa, SiHa, CaSki, C-
4-I and C33A (American Type Culture Collection, Rock-
ville, MD) were maintained in DMEM supplemented with
10% FCS and 2mM glutamine.
Immunohistochemistry
Serial sections (4–5 μm thick) of neutral formalin-fixed
and paraffin embedded tissues were used. The first section
was stained with hematoxylin-eosin to confirm the diag-
nosis. Three independent pathologists (G.F., L.Z. and
Y.A.) verified the diagnosis. Next sections were stained
with antibodies. Normal cervical epithelium was included
into every set of slides for staining as a negative control
[18]. The procedures of epitope retrieval, blocking of non-
specific binding and endogenous peroxidase activity,
incubation with the p16ink4a-specific monoclonal anti-
bodies (CINtec™ Histology Kit, DakoCytomation) werePage 2 of 10
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results, the slides, which had been exposed to the primary
antibodies, were treated with the EnVision™ +Dual Link
DakoCytomation reagent. The reaction was developed
with either AEC or DAB chromogen. The slides were coun-
terstained with Mayer's hematoxylin. To detect p16ink4a in
cells, they were grown on the HistoBond adhesive coated
slides (SMT Geraetehandel GmbH, Germany), fixed with
4% paraformaldehyde, washed with PBS and processed
similarly to the deparaffinized histological slides.
DNA and RNA preparations
DNAs and RNAs were isolated from frozen tissues or cells
by homogenization in the 4, 5 M solution of guanidine
isothiocyanate and centrifugation through cesium chlo-
ride cushion as described previously [28].
Bisulfite based cytosine methylation analysis of p16 INK4a
DNAs (1.5–3.0 μg) were denaturated by incubation in
solution of 0.35 M NaOH for 10 minutes at 37°C. The
reaction of bisulfite conversion was carried out in a solu-
tion of sodium bisulfite (3.1 M) and hydroquinone (0.6
mM) at pH 5.5 and 50°C during 4 hours. After desalting
DNAs were desulfonated by incubation in solution of 0.3
M NaOH at 37°C for 10 min, then the solution was neu-
tralized with 5 M ammonium acetate (pH 7.0) and DNAs
were ethanol-precipitated. The pellets were dissolved in
distilled H2O and the DNA aliquots (100–300 ng) were
used for the PCR amplifications by JumpStart RedTaq
DNA polymerase according to manufactur's procedure
(Sigma, USA) in 30-μkl reaction mixtures under the fol-
lowing conditions: 94°C, 4 min; 35 amplification cycles
(94°C, 30 s; 64°C, 60 s; 72°C, 30 s) and finally at 72°C,
5 min. The p16INK4a primers that corresponded to the
upper strand of bisulfite-modified DNA and did not con-
tain CpG dinucleotides in the original sequences were
used: sense 5' GAG GAG GGG TTG GTT GGT TAT TAG AG
(1115) and antisense 5' TAC CTA ATT CCA ATT CCC CTA
CAA AC (1418). The positions of the primers are given in
base pairs related to the gene sequence [GenBank: X94154
+ U12818]. In some cases the combined primer (5' M13+
sense primer) was used for direct sequencing of PCR prod-
uct [29]. The resulting PCR products were fractionated in
low melting agarose (Sigma), purified using QIAEX II kit
(Qiagen) and either used for automated sequencing on
DNA Sequencer (ABI Prism 3100-Avant Genetic Analyzer)
or were cloned into pGEM-T Easy vector (Promega, USA)
and then DNAs of individual clone were sequenced. The
same total PCR products were used for determination of
methylation status of p16 INK4a promoter region by of
MSP [30]. The primer sequences specific for methylated
(sense 5 ' TTA TTA GAG GGT GGG GCG GAT CGC, anti-
sense 5' GAC CCC GAA CCG CGA CCG TAA) and
unmethylated (sense 5' TTA TTA GAG GGT GGG GTG
GAT TGT, antisense 5' CAA CCC CAA ACC ACA ACC ATA
A) variant of p16INK4a and the conditions of amplifica-
tion were as described by Herman et al [30]. The positions
of these primers are indicated at the map of p16INK4 pro-
moter region (fig. 1a.)
RT-PCR
The mRNA level of p16INK4a gene was determined by
reverse transcription combined with polymerase chain
reaction (RT-PCR). RT was carried out in 20 μl reaction
mixture containing 1 μg of total cellular RNA, treated with
DNAase I (Invitrogene), 1× buffer (50 mM Tris, pH 8.3,
61.5 mM KCl, 3 mM MgCl2); 1 mM of each of dATP,
dTTP, dGTP and dCTP; 20 pmol of random hexamer; 200
U of reverse transcriptase (Superscript II Rnase H-, Invitro-
gen, USA) at 25°C for 10 min and then at 42°C for 50
min. PCR was performed with the primers: sense, 5' AGC
CTT CGG CTG ACT GGC TGG; antisense, 5' GCG CTG
CCC ATC ATC ATG AC under the following conditions:
94°C for 2 min; 26 cycles (94°C, 30 s; 58°C, 30 s; 72°C,
40 s), and finally at 72°C for 3 min. To control the con-
tent of the initial total mRNA, PCRs were carried out with
the primers for GAPDH (sense 5' ACC ACA GTC CAT GCC
ATC AC, antisense 5' TCC ACC ACC CTG TTG CTG TA)
and HPRT1 (sense 5' CTG GAT TAC ATC AAA GCA CTG,
antisense 5' GGA TTA TAC TGC CTG ACC AAG). The con-
ditions of PCR were as follow: 94°C, 3 min; (94°C, 30 s;
58°C, 30 s; 72°C, 1 min,) and 72°C, 10 min, 23 cycles for
GAPDH and 30 cycles for HPRT1. PCR products were
resolved on 2% agarose gels in the presence of ethidium
bromide and visualized by fluorescence in transmitted
ultraviolet light or transferred to membrane (Hybondand-
N+, Amersham Biosciences) and probed with p16INK4a-
specific P32 labeled internal oligonucleotide 5'CTG CCC
AAC GCA CCG AAT AGT TAC G [4].
Analysis of the oncogene E7 transcripts was performed
with the following primers: HPV16 sense, 5' CGG ACA
GAG CCC ATT ACA AT; antisense, 5' GAA CAG ATG GGG
CAC ACA AT; HPV18 sense, 5' GCT GAA CCA CAA CGT
CAC AC; antisense, 5'-GGT CGT CTG CTG AGC TTT CT.
The conditions of PCR were as follow: 94°C, 4 min;
(94°C, 30 s; 58°C, 30 s; 72°C, 90 s) 35 cycles and 72°C,
6 min.
Results
Analysis of the 5' CpG island methylation by MSP and 
bisulfite-modified DNA sequencing
First the methylation status of the region around the p16
INK4a translation start site was analyzed by methylation-
specific PCR (MSP) with commonly used primers (see
scheme, fig. 1) [30]. Exactly this region of the p16 INK4a
CpG island was reported to be methylated in many types
of tumors including cervical squamous cell carcinomas
[3,22-27,30]. The presence of methylated alleles was
revealed in 6 out of 26 (23%) squamous cell carcinomasPage 3 of 10
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Bisulfite-modified sequencing analysis of p16 INK4a 5' CpG island in cervical carcinomas and cervical cancer cell linesF gure 1
Bisulfite-modified sequencing analysis of p16 INK4a 5' CpG island in cervical carcinomas and cervical cancer 
cell lines. A. Schematic representation of the p16 INK4a 5' region: broken arrow indicates the location of the translation start 
site; figures above horizontal line indicate the numbers of CpG dinucleotides relative to the translation start site; vertical lines 
indicate Hpa II recognition sites; horizontal arrows indicate positions of primers for MSP analysis [30], + indicates MSP-positive 
samples; each row of circles represents a sequence of total PCR product generated from bisulfite-treated DNA of tumor (T) 
and normal adjacent tissue (N) or sequence of cloned PCR product (cl), one clone out 5 identical clones is presented; figures 
on the left side of scheme indicate specimen numbers; open circles – unmethylated cytosine, gray circles – partially methylated 
cytosine, black circles – methylated cytosine, triangles – status of cytosine is not detected. B. Chromatograms showing CpG-
dinucleotides with unmethylated and partially methylated cytosines in some normal and tumor tissues. Numbers of CpG-dinu-
cleotides and samples are indicated, as in A.
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tumors. There were methylated alleles in none of the 5
cervical cancer cell lines. Then methylation status of half
of tumor and normal samples and 5 cell lines were veri-
fied by the bisulfite-based DNA sequencing. The methyla-
tion status of 26 CpG dinucleotides localized within the
200 bp-long fragment of DNA around the p16 INK4a
translation start site was evaluated. Samples containing
methylated alleles of gene as determined by MSP are
marked by + (fig. 1a). Bisulfite-modified DNA sequencing
analysis has not revealed extensive methylation of this
region in either 13 carcinomas or 5 carcinoma cell lines.
Sequencing analysis of total PCR product generated from
this region revealed a varied number of solitary partially
methylated CpG sites in DNA of some tumors and carci-
noma cell lines, as well as in DNA of some normal tissues.
Examples of partially methylated CpG sites are presented
on fig. 1b. There was no essential difference in mosaic pat-
terns of partially methylated CpG sites of tumors and nor-
mal tissues. In some cases the number of partially
methylated CpG sites was greater in normal tissues than in
tumors (fig. 1a, samples 2 and 12). Moreover, the number
of partially methylated CpG sites in some of MSP-positive
carcinomas was less than in MSP-negative carcinomas had
(fig 1a, 7T, 10 T and 13T respectively). The distribution of
partially methylated CpG dinucleotides within examined
region varied in different samples. There was no preferen-
tial association of partially methylated CpG dinucleotides
with any transcriptional factor binding site. The analysis
of the cloned PCR products showed that 5 out of 5 clones
contained only unmethylated CpG sites (fig. 1a and 1b, cl.
10T; Caski, cl.; one out of 5 identical clones is presented).
These results are compatible with those for the population
of DNA molecules (total PCR product) and demonstrate
that methylation of certain CpG sites within the p16
INK4a 5'CpG islands is a rare event. Thus, no extensive
methylation of the examined region was revealed in HR-
HPV-positive cervical carcinomas, including carcinomas
positive by MSP in our hands.
Next we examined methylation status of 3 HpaII recogni-
tion sites located around putative multiple sites of p16
transcription initiation (300 bp upstream of translation
start site indicated on scheme, fig. 1). It has been demon-
strated previously by CAT assay and bisulfite genomic
sequencing that methylation of these critical HpaII sites
significantly down-regulates p16 promoter activity [4,31].
Analysis of this region by HpaII-methylation-sensitive
PCR revealed the presence of methylated alleles only in 1
out of 26 carcinomas. Methylation of these critical HpaII
sites was not detected in any cancer cell lines or normal
tissues (data are not presented). These findings demon-
strate that methylation of critical HpaII sites in the region
of putative transcription start sites is a rare event in HPV-
positive cervical carcinomas.
Expression analysis of p16 INK4a by RT-PCR
To understand whether mosaic methylation of 5'CpG
island can modulate p16 INK4a transcription, the levels of
mRNA were analyzed in all samples listed in fig 1. A rep-
resentative example of the RT-PCR analysis is shown in fig
2. All carcinomas expressed HPV-E7 oncogene. The up-
regulation of p16 INK4a transcription was detected in all
carcinomas and carcinoma cell lines except for case No 1
(table 1 and fig 2, 1T). Independently of the number of
partially methylated CpG sites within 5'CpG island, the
mRNA levels were three- to 30-fold higher in carcinomas
then in normal adjacent tissues. A rare case of the com-
plete absence of the p16 INK4a mRNA in tumor No 1
expressing E7 viral oncogene was not related to hyper-
methylation of the examined regions, which was com-
pletely unmethylated in this carcinoma (fig. 1, 1T). Thus,
random methylation of some CpG sites in 5'CpG islands
does not prevent the p16 INK4a transcriptional activation
in HR-HPV-positive cervical carcinomas.
Expression analysis of p16ink4a by immunohistochemistry
Unlike RT-PCR analysis, the p16ink4a immunostaining
allows to estimate the amount of tumor cells expressing
the protein. Rpresentative examples of the p16ink4a immu-
noreactivity are shown in fig. 3 and the results of the anal-
ysis are summarized in table 1. Cervical normal cells are
not stained for p16ink4a, as expected (fig. 3g). On the other
hand, the technical procedure used in this study allows to
reveal the p16ink4a expression in all HR-HPV-positive cell
lines SiHa, HeLa, Caski, C4-I and in HPV-negative line
C33A, in which pRb is inactivated by mutation [8]. As
expected, a strong predominantly cytoplasmic p16ink4a
immunoreactivity was detected in a majority of cells [17].
The relative number of stained nuclei varied in different
cell lines from 5 to more than 25% (fig 3a,b,c). A cytoplas-
mic immunoreactivity in the majority of cells was also
revealed for all tumors with p16 INK4a transcriptional
activation (fig. 3d,e,f) Tumors differed from each other by
the number of stained nuclei like cell lines (from less than
1% to more than 25%). Carcinoma No 1 with the com-
plete absence of mRNA did not show immunohistochem-
ically detectable p16ink4a expression either in the
cytoplasm or in the nuclei, confirming specificity of the
p16ink4a immunoreactivity (table 1 and fig 2, 1T). The
tumors that contained methylated alleles of gene
(detected by MSP) exhibited the p16ink4a immunoreactiv-
ity. In some cases they displayed strong diffuse p16ink4a
staining (fig. 3f). The percentage of stained nuclei did not
correlate with the mRNA levels. The lowest number of
stained nuclei was detected in carcinoma with the highest
mRNA level (table 1 and fig. 2, sample 3). Thus, the tran-
scriptional activation of p16 INK4a correlates with
p16ink4a cytoplasmic staining but does not influence the
level of nuclear staining. The random methylation of
some CpG sites within 5'CpG islands does not interferePage 5 of 10
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of HR-HPV-positive cervical tumors and cancer cell lines.
Discussion
Bisulfite-modified DNA sequencing analysis demon-
strated that there was not extensive methylation within
the commonly examined region of the p16 INK4a 5'CpG
island either in13 primary cervical carcinomas or in 5 can-
cer cell lines. Along with completely unmethylated
tumors, some tumors, as well as matched normal tissues,
displayed a random location of few partially methylated
CpG sites and the lack of completely methylated CpG sites
within the examined region. Revealed methylation pat-
terns of the population of DNA molecules and analysis of
individual DNA molecules (see fig. 1a, clones) show that
hypermethylation of certain CpG sites does not take place
in the majority of cells. Our results are consistent with the
unique study in which the methylation status of a short
DNA fragment within this region has been evaluated by
pyrosequencing in cervical intraepithelial neoplasia
(CIN). Partial methylation (6–24%) of 1–3 out of 6 CpG
sites was demonstrated in MSP-positive CIN [32]. The par-
tial random methylation that has been revealed in some
carcinomas and normal tissues cannot exclude the pres-
ence of hypermethylated alleles in some cells that can be
detected by MSP analysis. MSP is simple, highly sensitive
(1 methylated allele in the presence of 105 unmethylated
alleles) and non-quantitative test. A minimal degree of
methylation can be registered as "positive methylation"
depending on the original DNA concentration, primer
sets and the number of cycles used for PCR [32,33].
Indeed in different populationsof patients the p16 INK4a
methylation was determined in 25–57% of invasive cervi-
cal squamous cell carcinomas (I-IV FIGO stages) by MSP
[22-27]. Our results of MSP analysis of the same p16
INK4a region with the same set of primers in invasive SCC
(I-III FIGO stages) are in close agreement with these find-
ings. However methylation patterns determined by
bisulfite sequencing show that the p16 INK4a 5'CpG
island hypermethylaion is not typical for the majority of
cancer cells in these carcinomas. Thus, methylation can-
not be an effective marker of the HR-HPV-positive cancer
cells.
It has been demonstrated previously by CAT assay and
bisulfite genomic sequencing that methylation of critical
CpG sites located around putative multiple sites of the
transcription initiation significantly down-regulates the
p16 INK4a promoter activity. On the contrary, p16 INK4a
transcription can occur even in the presence of a relatively
heavy methylation of CpG sites surrounding the ATG ini-
tiation codon (the region commonly examined by MSP)
[4,31] Our data are in an agreement with these findings.
All cervical tumors and cancer cell lines with partial meth-
ylation determined by bisulfite sequencing (including
MSP-positive samples) showed high level of p16 INK4a
mRNA as compared with normal tissues. (All of these car-
cinomas had no methylation of critical HpaII sites near
Table 1: Methylation and expression of gene p16 INK4a in HR-HPV-positive cervical carcinomas and cervical cancer cell lines
Carcinoma/cells line Methylation status of 5' CpG island ** RT-PCR *** Immunochemical detection
Number of stained nuclei (%) Cytoplasmic staining
1 1 - 0 Negative
2 3 + <1
3 4 +
4 0 + <5
5 0 + Positive in the majority of cancer cells




10 8* + >25
11 3 +
12 0 +
13 10 + nt nt
C4-I 0 + <5
HeLa 2 + 10–15 Positive in the majority of cells
SiHa 6 +
C33A 0 +
CaSki 0 + >25
* tumors that have methylated alleles, as determined by MSP
** number of partially methylated CpG dinucleotides out of 26 CpG dinucleotides in 5' region of p16INK4a examined by bisulfite-modified DNA 
sequencing (see fig.1)
*** more than 3 fold increase of the mRNA level in tumor compared to normal tissuesPage 6 of 10
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some CpG sites in the region around the translation start
site does not prevent the p16 INK4a transcriptional activa-
tion. Transcriptional activation of p16 INK4a was strongly
associated with the HPV-E7 oncogene expression. These
findings have confirmed that activation of p16 INK4a
expression due to the HPV-E7 expression takes place at the
level of transcription [7]. We conclude that partial ran-
dom methylation and the p16 INK4a MSP-positivity are
compatible with the activation of the transcription due to
the HPV-E7 expression. Unfortunately, the p16 INK4a
transcriptional activation and HR-HPV-E7 oncogene
expression were not analyzed in most of the studies dem-
onstrating methylation of p16 INK4a by MSP in some por-
tion of cervical carcinomas [22-27]. Only in one of these
studies the p16ink4a expression was evaluated by immuno-
histochemical technique, however the authors did not
find any correlation between methylation stutus deter-
mined by MSP and immunohistochemical staining of
p16ink4a [25].
Transcriptional activation of p16 INK4a correlated with
p16ink4a cytoplasmic staining in the majority of tumor
cells in all samples, but did not correlate with the number
of stained nuclei. It is generally believed that p16ink4a
functions as Cdk-inhibitor in the nucleus. It has been
demonstrated that in normal cells p16ink4a localizes
mainly in nuclei [34]. On the contrary, a loss of p16ink4a
nuclear staining and retention of cytoplasmic staining
have been observed earlier in different tumors including
cervical carcinomas and cell lines [17,35,36]. Cytoplasmic
staining is controversial and classified as unspecific as well
as specific staining in several studies [35-37]. Recently it
was demonstrated that p16ink4a was present in protein
complexes and bind with Cdk4/6 in both cytoplasmic and
nuclear fractions of several cancer cell lines [37]. Authors
believe that the p16ink4a cytoplasmic staining is specific.
Functional p16ink4a was revealed in cytoplasmic fraction
of Rb-functional and Rb-inactivated tumor cells. Mecha-
nism of cytoplasmic p16ink4a accumulation in cancer cells
is unknown but it is evident that the accumulation of
p16ink4a in cytoplasm of tumor cells occurs independently
of a functional status of pRb. Our data are in line with this
observation. They demonstrate that cytoplasmic staining
and the lack or low number of stained nuclei do not mean
the absence of p16 INK4a transcriptional activation in HR-
HPV-positive cervical carcinomas. In the case of the com-
plete absence of mRNA (carcinoma No 1), the p16ink4a-
specific antibodies did not reveal any cytoplasmic staining
confirming specificity of the p16ink4a immunoreactivity.
So, it is impossible to exclude that a strong uniform cyto-
plasmic staining may indicate the presence of cancer cells
with deregulated expression of viral oncogenes, pRb inac-
tivation and p16 INK4a transcriptional activation. Specif-
Expression analysis of p16 INK4a in cervical carcinomas by RT-PCRFigure 2
Expression analysis of p16 INK4a in cervical carcinomas by RT-PCR. Top, electrophoregram after Southern blot 
hybridization with the p16INK4a-specific radioactive probe. Middle and bottom, electrophoregrams after ethidium bromide 
staining. Middle, RT-PCR with viral E7 gene-specific primers as a control for E7 expression. Bottom, RT-PCR with the GAPDH-
specific primers as a control for stability and concentration of RNA. T – carcinomas, N – normal tissue. Specimen numbers 
above the upper lines are as on fig. 1 and table 1.Page 7 of 10
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Immunochemical detection of p16INK4a in cervical carcinoma and cervical cancer cell linesFigure 3
Immunochemical detection of p16INK4a in cervical carcinoma and cervical cancer cell lines. Cervical cancer cell 
lines: a – C4-I; b – SiHa; c – CaSki; primary carcinomas (numbers are indicated as on fig. 1, 2 and table 1): d – case 2, e – case 
6, f – case 7, g – cervical epithelium adjacent to tumor. Original magnification: a-f × 40; g × 20.
BMC Cancer 2007, 7:47 http://www.biomedcentral.com/1471-2407/7/47icity of p16ink4a cytoplasmic staining in parallel with
transcriptional activation needs to be further investigated.
It is possible that further deregulation of the pRb/p16
pathway (lack of p16ink4a transportation to nuclei)
appears during progression from CIN to carcinomas.
These studies may help to avoid discrepancies in interpre-
tation of the p16ink4a immunoreactivity.
On the other hand, HPV-positive invasive carcinomas in
which the HPV oncogene E7 is expressed but the p16ink4a
overexpression does not occur do exist [[17] and case No
1 in our study]. These carcinomas are rare examples of
simultaneous inactivation of both p16ink4a and pRb.
Mechanisms of the disruption of the regulatory feedback
in pRb/p16 pathway in these carcinomas are not estab-
lished. The lack of the p16INK4a 5'CpG island hyper-
methylation in the carcinoma No 1 suggests that there is
another cause of the p16ink4a-negativity except hyper-
methylation.
Conclusion
The p16INK4a 5'CpG island hypermethylaion is not a fre-
quent event in HR-HPV-positive cervical carcinomas.
Cytoplasmic accumulation of p16ink4a is a feature of cervi-
cal carcinomas. Our data confirm other previous studies
claiming specific a p16INK4a up-regulation in the major-
ity of HR-HPV positive cervical carcinomas at both the
protein and mRNA levels. These data demonstrate that the
5'CpG island hypermethylation of the gene can not be an
effective marker of HR-HPV-positive cancer cells with up-
regulated p16ink4a expression.
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